formation, [14] [15] [16] [17] blood TPO, IL-6 and IL-11 levels in this disease, since TPO is a factor in the development of marrow megakaryocytosis but the major megakaryocytic proliferation and differentiation its elevated blood levels may represent a secondary immune factor and IL-6, IL-11 are potent differentiating factors.
Introduction
From July 1988 to March 1996, 45 consecutive patients with AMM and 17 normal volunteers were studied. A diagnosis of Many cytokines have been found to implicate megakaryopo-AMM was made by the clinical features of leukoerythroblastic iesis. Among them, interleukin-3 (IL-3) is a potent stimulant of blood picture, splenomegaly and marrow fibrosis without CFU-Meg (colony forming unit-megakaryocyte) proliferation, underlying etiology. Marrow fibrosis was assayed by tribut has little effect on megakaryocyte maturation.
1,2 IL-6, ILchrome and reticulin fiber stain. Patients with positive Phila-11, stem cell factor (SCF) and leukemia inhibitor factor (LIF) delphia chromosome or positive BCR analysis, or with display scant to no megakaryocyte colony-stimulating activity transitional myelodysplasia-myelofibrosis, 26 or with acute as single agents in vitro, but can augment the effect of IL-3 on myelofibrosis 27 were excluded. CFU-Meg growth. [2] [3] [4] The predominant effects of IL-6 and IL-11 are in megakaryocyte maturation. [3] [4] [5] IL-6 and IL-11 in vivo caused predominantly elevated platelet counts without major Blood samples effects on the numbers of other blood cells. [6] [7] [8] [9] USA), was used as the captured antibody in this ELISA assay. 28 Spleen size evaluation Briefly, this antibody was coated on to 96-well EIA plates, then samples and the recombinant human TPO (rHUTPO), used Spleen size was measured as the distance in centimeters between the palpated lower border and the left costal margin. as standard, were added. Signal antibody using rabbit antirHUTPO:HRPO conjugate were added after the uncaptured proteins were washed. TMB-peroxidase substrate/peroxidase solution was added for color development and read OD at Statistical methods 450 nm minus 650 nm. In order to confirm the validity of this TPO assay, sensitivity and specificity tests were done. The senAll values were expressed as mean ± s.e. For analysis of statistical significance between two groups, Student's two-tailed sitivity of this assay was determined by adding two standard deviations to the mean optical density (OD 450 minus unpaired t-test was used; P Ͻ 0.05 was considered significant. Correlation between two variables was evaluated using Pear-650 nm) value of 30 zero standard duplicates and calculating the corresponding concentrations from the standard curve son's coefficient of correlation method. Linear regression analysis was performed using the method of least squares.
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(linear regression). The detection range of the assay was defined by the linear portion of the standard curve. The specificity of the assay was tested using human recombinant cytokines spiked into fetal calf serum and compared with TPO. Results The following cytokines were used: erythropoietin, IL-6, macrophage colony-stimulating factor (M-CSF), leukemia TPO assay inhibitory factor (LIF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor
The sensitivity of this assay was 9.9 pg/ml. Assay specificity was tested with recombinant cytokines: EPO, IL-6, M-CSF, LIF, (G-CSF), IL-1␤, stem cell factor (SCF), interferon ␥ and IL-7 (Amgen); insulin (Boehringer Mannheim, Indianapolis, IN, GM-CSF, IL-1␤, SCF, INF␥, IL-7, insulin, ␤-FGF, IL-11, and IL-3 at 100 ng/ml and 100 pg/ml, and no gross reactivity of these USA); basic fibroblast growth factor (␤-FGF), IL-11 and IL-3 (Genzyme, Cambridge, MA, USA).
cytokines in this assay was found (data not shown).
TPO levels IL-6 assay
The ELISA kit purchased from R&D Systems (Minneapolis, Because some samples were collected in serum and some in plasma, a statistical calculation of linear regression analysis MN, USA) was used. Monoclonal antibody specific for IL-6 was used as the captured antibody. Standard and samples between serum and plasma TPO levels was done. Thirteen patients with AMM who had serum and plasma collected simwere then pipetted into the precoated captured antibody plates. After washing away the unbound protein, an enzymeultaneously were analyzed. Regression analysis yielded the equation y = −20 + 0.87x (P Ͻ 0.0001 r = 0.96), y represented linked polyclonal antibody specific for IL-6 was added to sandwich the immobilized IL-6. Color development was then plasma TPO value, while x represented serum TPO values ( Figure 1 ). Accordingly, plasma TPO values were then conread at 450 nm. Each sample was measured in duplicates.
verted to serum TPO values using this equation. Figure 2 shows that blood TPO levels in patients with AMM were significantly higher than in normal volunteers (n = 17), with IL-11 assay mean ± s.e. of 693.20 ± 82.66 (pg/ml) and 185.80 ± 26.62 (pg/ml), respectively (P Ͻ 0.0001). Blood TPO levels in The ELISA kit was purchased from R&D Systems. IL-11 monoclonal antibody was used as the captured antibody. Similar patients with AMM ranged from 52.4 to 1901 (pg/ml), while procedures were done as described in the IL-6 assay according to the manufacturer's instructions. Duplicate samples were measured in each analysis.
Marrow megakaryocytes and degree of fibrosis evaluation
Trephine bone marrow biopsy specimens were evaluated for the numbers of megakaryocytes and degree of fibrosis as described previously.
29-31 Bone marrow megakaryocyte numbers were evaluated by counting the numbers of megakaryocytes in five high power fields. The mean of these numbers was counted as the number of marrow megakaryocytes. Degree of bone marrow fibrosis was evaluated by the sum of the degree of marrow megakaryocytes. Degree of bone marrow fibrosis was evaluated by the sum of the degree (0-4+) was a discrepancy, the specimen was re-examined.
Figure 2
Blood TPO levels (pg/ml) in 45 patients with agnogenic myeloid metaplasia (MF) compared with 17 normal volunteer controls (CTL). Blood TPO levels were measured by the ELISA assay of the Figure 4 Correlation between serum TPO levels and blood serum samples or the plasma samples, the values of plasma samples platelet counts. were then converted to serum values (see text for details). Results were expressed as mean ± s.e. mostly atypical, single, hypo-or hyper-lobulated, and many in normal controls, the range extended from 10.5 to 375. 4 of them appeared in clusters. No correlation between blood (pg/ml).
TPO levels and number of marrow megakaryocytes was found (data not shown). Patients with low blood TPO levels were also found to have abundant marrow megakaryocyte numbers
Correlation between serum TPO and WBC counts, with many atypical megakaryocytes.
degree of splenomegaly, and degree of marrow fibrosis Blood IL-6 levels No significant correlation was found between serum TPO and WBC counts, or degree of splenomegaly, but serum TPO levSerum IL-6 levels in AMM (n = 37) patients were 21.64 ± 4.10 els did correlate to the degree of marrow fibrosis (P = 0.0078, (pg/ml), significantly higher than controls (n = 12, mean ± s.e. r = 0.5006) (n = 27) ( Figure 3) . of 2.35 ± 1.34 pg/ml) (P Ͻ 0.001) ( Figure 5 ). No significant correlation was found between serum IL-6 levels and WBC counts, platelet counts, degree of fibrosis, degree of Correlation between serum TPO, marrow splenomegaly, blood TPO levels, or number of marrow megakaryocytes and blood platelets counts megakaryocytes. No significant correlation was found between serum TPO levels and blood platelet counts as shown in Figure 4 . All patients were found to have increased marrow megakaryocyte numBlood IL-11 levels bers as compared with controls. The megakaryocytes were Many patients and controls were found to have undetectable levels. No significance difference was detected between patients with AMM and controls.
Figure 3
Correlation between blood TPO levels and degree of bone marrow fibrosis in patients with AMM (n = 27). Degrees of fibrosis were measured by the sum of degree (0-4) evaluated by the Figure 5 Serum IL-6 levels in 37 patients with agnogenic myeloid metaplasia (MF) and 12 normal volunteer controls. Results were reticulin fiber and collagen fiber stain, respectively, as described in Materials and methods.
expressed as mean ± s.e.
Patients with thrombocytosis mRNA levels, platelet abilities to bind, degrade and internalize TPO (namely, the numbers of receptors or abnormalities of c-MPL receptors) will be necessary to answer the mechFourteen patients with AMM had platelet counts over 500 × 10 3 per l. The blood TPO levels in these patients (mean ± anisms of high TPO in this disease. We also found that blood TPO levels are correlated with s.e. of 599.1 ± 168.6 pg/ml) were also found to be higher than in controls (P Ͻ 0.0001). Among these patients, eight had the degree of bone marrow fibrosis (Figure 3) . Recently, Yan et al 42, 43 found that mice induced to overexpress TPO by elevated blood TPO levels while only four patients had elevated IL-6 values.
retroviral-mediated gene transfer by transplanting bone marrow cells infected with an inserted TPO gene developed myelofibrosis and osteosclerosis. These findings plus our present study suggest that TPO may be involved in the pathogenesis Discussion of fibrosis in AMM; the mechanism could be that high TPO levels stimulate the production of megakaryocytes which in The present study has shown that blood levels of TPO are significantly higher in patients with AMM than in normal conturn stimulate the production of TGF-␤ and platelet growth factors leading to myelofibrosis. 44 Alternatively, high blood trols ( Figure 2 ) and blood TPO levels are not correlated with blood platelet counts (Figure 4 ) or bone marrow megakary-TPO levels in AMM may represent an epiphenomenon of an underlying stem cell disorder which results in developing ocyte mass. We also found that blood TPO levels are significantly higher in patients with essential thrombocythemia and abnormal megakaryocytes, marrow fibrosis and high blood TPO levels. polycythemia vera, than in patients with secondary thrombocytosis or normal controls. 34 These findings are in contrast We also found blood IL-6 levels are significantly elevated in patients with AMM as compared with controls. In previous to the relationship between erythropoietin levels and RBC values in these patients. Through feed-back mechanisms, studies, blood IL-6 levels were found to be significantly elevated in patients with reactive thrombocytosis, while normal or serum erythropoietin (EPO) is suppressed in patients with polycythemia vera 35 and in AMM serum EPO is, in general, undetectable values were found in patients with clonal thrombocytosis. [45] [46] [47] The discrepancies are probably related to the inversely correlated with the degree of anemia. 36 However, the present study shows that in AMM blood TPO levels are difference in the methods used; a bioassay using an IL-6-dependent B 9 cell line was used in most of the reports pubnot inversely correlated with platelets counts as blood EPO levels are correlated inversely with Hb levels or RBC mass.
lished, and very few patients with AMM were included and assayed. IL-6 is an integral component of the biological Published explanations of the mechanisms of high blood TPO levels are conflicting. Emmons et al 37 found that bone response in acute phase reactions, inflammations and immune reactions. [48] [49] [50] [51] [52] [53] High production of IL-6 has been found in marrow megakaryocyte mass, reflected in the rate of platelet production, is the major determinant of blood TPO level, notautoimmune diseases such as rheumatoid arthritis 51 and mesangial proliferative glomerulonephritis. 52 Since circulating ing that markedly elevated blood TPO levels were found in aplastic anemic patients, low or undetectable TPO levels were immune complex 48 and high soluble IL-2 receptors 54 have been detected in AMM, the elevated blood IL-6 levels in this found in idiopathic thrombocytopenic purpura or post-transfusion or drug-induced thrombocytopenic patients. Others, disease are probably related to the immune mechanism. Blood IL-11 levels were not elevated or were undetectable however, have found blood TPO levels are related to the platelet mass; Fielder et al 38 found that blood TPO levels were in AMM as compared with controls. IL-11 is a pleiotropic growth factor initially detected in the conditioned medium related to the c-mpl-mediated binding to platelets. They observed no difference in TPO mRNA levels between cderived from the immortalized primate bone marrow stromal cell line PU-34. 55 In vitro in synergy with other growth factors mpl−/− and wild-type mice, but platelets from c-mpl−/− mice, lacking TPO receptors, were unable to degrade, bind and it promotes the proliferation of various hematopoietic stem cells and is also involved in the maturation of early megakaryinternalize TPO, leading to high blood TPO levels. Kuter et al 39 also observed a reciprocal relationship of blood TPO levocytes. 56,57 Whether IL-11 plays a role in the bone marrow milieu to cause bone marrow megakaryocytosis and clusters els to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Therefore, published reports of megakaryocytes will need further study. Among 14 patients with AMM with thrombocytosis, eight indicate that blood TPO levels are regulated by platelet counts and/or megakaryocyte mass by binding of TPO through c-MPL (57%) patients were found to have elevated blood TPO levels, while only four (23%) had elevated blood IL-6 values. receptors in platelets and megakaryocytes and subsequent degradation and internalization of TPO as demonstrated by
Reactive thrombocytosis with high IL-6 levels has no atypical megakaryocytosis [45] [46] [47] while these features are often seen in the in vitro model. 40 The present study, however, found no correlation between blood TPO levels and platelet counts or AMM. These findings suggest that IL-6 probably plays a minor role in causing thrombocytosis in this disease. marrow megakaryocyte mass. Since previous studies 41 have reported that variations in evaluating bone marrow megakaryocytes could be as large as 300-fold, and spleen megakaryocyte mass was not evaluated by the present study, evaluation between blood TPO levels and megakaryocyte mass could not be adequately determined. The fact that all patients with AMM Acknowledgements have increased numbers of marrow megakaryocytes and patients with elevated platelet counts also were found to have high blood TPO levels, the high blood TPO levels found in This work was supported in part by the Lee Streich Memorial Fund For Cancer Research and Dworetz-Wolf-Hoffman Founpatients with AMM are not consistent with previously published explanations of the effects of the increased megakarydation. TPO ELISA reagents, including TPO antibody, were generous gifts from Janet Nichol, Amgen, Thousand Oaks, ocyte mass or the increased platelet mass, which should lead to low blood TPO levels. Further studies to measure TPO CA, USA.
